News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neurogen Says Insomnia Drug Safe In Phase I Trial
December 8, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dec 8 (Reuters) - Neurogen Corp. (NRGN.O: Quote, Profile, Research) on Thursday said the results of its Phase I multiple ascending dose trial for insomnia drug NG2-73 showed that the compound was safe and well tolerated.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
IPO
Axiom plans Hong Kong IPO, hoping to carve new path for US biotechs
July 21, 2026
·
3 min read
·
Gabrielle Masson
Psychedelics
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
July 20, 2026
·
3 min read
·
Heather McKenzie
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
July 20, 2026
·
2 min read
·
Tristan Manalac
Drug Development
India’s life sciences sector at turning point for innovation: Report
July 17, 2026
·
2 min read
·
Angela Gabriel
